» Articles » PMID: 35495153

Schizophrenia Risk Mediated by MicroRNA Target Genes Overlapped by Genome-Wide Rare Copy Number Variation in 22q11.2 Deletion Syndrome

Overview
Journal Front Genet
Date 2022 May 2
PMID 35495153
Authors
Affiliations
Soon will be listed here.
Abstract

The 22q11.2 deletion is associated with >20-fold increased risk for schizophrenia. The presence of gene in the 22q11.2 deletion region has suggested microRNA (miRNA) dysregulation as possibly contributing to this risk. We therefore investigated the role of miRNA target genes in the context of previously identified genome-wide risk for schizophrenia conveyed by additional copy number variation (CNV) in 22q11.2 deletion syndrome (22q11.2DS). Using a cohort of individuals with 22q11.2DS and documented additional rare CNVs overlapping protein coding genes, we compared those with schizophrenia ( = 100) to those with no psychotic illness ( = 118), assessing for rare CNVs that overlapped experimentally supported miRNA target genes. We further characterized the contributing miRNA target genes using gene set enrichment analyses and identified the miRNAs most implicated. Consistent with our hypothesis, we found a significantly higher proportion of individuals in the schizophrenia than in the non-psychotic group to have an additional rare CNV that overlapped one or more miRNA target genes (odds ratio = 2.12, = 0.0138). Gene set analyses identified an enrichment of FMRP targets and genes involved in nervous system development and postsynaptic density amongst these miRNA target genes in the schizophrenia group. The miRNAs most implicated included miR-17-5p, miR-34a-5p and miR-124-3p. These results provide initial correlational evidence in support of a possible role for miRNA perturbation involving genes affected by rare genome-wide CNVs in the elevated risk for schizophrenia in 22q11.2DS, consistent with the multi-hit and multi-layered genetic mechanisms implicated in this and other forms of schizophrenia.

Citing Articles

Next-generation sequencing profiling of miRNAs in individuals with 22q11.2 deletion syndrome revealed altered expression of miR-185-5p.

Dantas A, Nunes B, Nunes N, Galante P, Asprino P, Ota V Hum Genomics. 2024; 18(1):64.

PMID: 38872198 PMC: 11170780. DOI: 10.1186/s40246-024-00625-5.


Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors.

Cillo F, Coppola E, Habetswallner F, Cecere F, Pignata L, Toriello E Genes (Basel). 2024; 15(3).

PMID: 38540380 PMC: 10969806. DOI: 10.3390/genes15030321.


Polygenic risk for triglyceride levels in the presence of a high impact rare variant.

Ying S, Heung T, Thiruvahindrapuram B, Engchuan W, Yin Y, Blagojevic C BMC Med Genomics. 2023; 16(1):281.

PMID: 37940981 PMC: 10634078. DOI: 10.1186/s12920-023-01717-2.


Identification of key long non-coding RNA-associated competing endogenous RNA axes in Brodmann Area 10 brain region of schizophrenia patients.

Sabaie H, Gholipour M, Asadi M, Abed S, Sharifi-Bonab M, Taheri M Front Psychiatry. 2022; 13:1010977.

PMID: 36405929 PMC: 9671706. DOI: 10.3389/fpsyt.2022.1010977.


Global alteration of colonic microRNAome landscape associated with inflammatory bowel disease.

Boros E, Hegedus Z, Kellermayer Z, Balogh P, Nagy I Front Immunol. 2022; 13:991346.

PMID: 36177008 PMC: 9513375. DOI: 10.3389/fimmu.2022.991346.

References
1.
Jin P, Zarnescu D, Ceman S, Nakamoto M, Mowrey J, Jongens T . Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci. 2004; 7(2):113-7. DOI: 10.1038/nn1174. View

2.
Riolo G, Cantara S, Marzocchi C, Ricci C . miRNA Targets: From Prediction Tools to Experimental Validation. Methods Protoc. 2020; 4(1). PMC: 7839038. DOI: 10.3390/mps4010001. View

3.
Cleynen I, Engchuan W, Hestand M, Heung T, Holleman A, Johnston H . Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Mol Psychiatry. 2020; 26(8):4496-4510. PMC: 7396297. DOI: 10.1038/s41380-020-0654-3. View

4.
Roy B, Dunbar M, Shelton R, Dwivedi Y . Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder. Neuropsychopharmacology. 2016; 42(4):864-875. PMC: 5312059. DOI: 10.1038/npp.2016.175. View

5.
Felekkis K, Voskarides K, Dweep H, Sticht C, Gretz N, Deltas C . Increased number of microRNA target sites in genes encoded in CNV regions. Evidence for an evolutionary genomic interaction. Mol Biol Evol. 2011; 28(9):2421-4. DOI: 10.1093/molbev/msr078. View